{
  "retracted": false,
  "timestamp": 1531699200000,
  "updates": [
    {
      "timestamp": 1574864742115,
      "identifier": {
        "doi": "10.3389/fimmu.2018.01641"
      },
      "type": "corrigendum"
    }
  ],
  "identifier": {
    "doi": "10.3389/fimmu.2018.01355"
  },
  "journal": "Frontiers in Immunology",
  "publisher": "Frontiers Media SA",
  "title": "Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Childrenâ€™s Oncology Group Study ANBL0931"
}
